Back to Market返回行情

ATRC AtriCure, Inc.

USHealthcare
$34.28-0.81%ClosedMarket Cap: $1.74B

As of 2026-07-10 16:00

Why ATRC matters now

AtriCure, Inc. (ATRC) is a US stock in Healthcare. The latest InvestLog snapshot shows $34.28 with -0.81% on the session and $1.74B in market capitalization; recent performance reads 1-month +0.00% and YTD -27.20%.

The latest financial table shown here is Q1 2026, with revenue of $141.2M, net income of $108.0K, and EPS of $0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.7%.

The latest indexable market news headline is "AtriCure to Announce Second Quarter 2026 Financial Results" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $55.00; recent insider activity includes Prange Karen filing S-Sale; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.83

P/S

2.64

EV/EBITDA

56.16

DCF Value

$-3.03

FCF Yield

3.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.5%

Operating Margin

-0.4%

Net Margin

-0.8%

ROE

-1.0%

ROA

-0.7%

ROIC

-0.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$141.2M$108.0K$0.00
Q4 2025$140.5M$1.8M$0.04
FY 2025$534.5M$-11.4M$-0.24
Q3 2025$134.3M$-267.0K$-0.01

Analyst Ratings

Consensus

Buy

Target (Consensus)

$51.33

Target (Median)

$55.00

Target Range

$44.00 - $55.00

Strong Buy: 3Buy: 4Hold: 2Sell: 0Strong Sell: 0
Canaccord GenuityBuy
2026-05-06
BTIGBuy
2026-02-18
Canaccord GenuityBuy
2026-02-18
OppenheimerPerform
2026-02-18
CitizensMarket Outperform
2026-02-18

Trading Activity

Insider Trades

Prange Karendirector
Sell2026-05-22
WHITE ROBERT S.director
Sell2026-05-20
WEHRWEIN SVENdirector
Sell2026-05-20
GROVES REGINA Edirector
Sell2026-05-20
JOHNSON B KRISTINEdirector
Sell2026-05-20

Congress Trades

Gilbert CisnerosBuy
2026-04-08

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

1.26

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.